Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Day, R.
Right arrow Articles by Fisher, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Day, R.
Right arrow Articles by Fisher, B.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Journal of Clinical Oncology, Vol 17, Issue 9 (September), 1999: 2659
© 1999 American Society for Clinical Oncology

Health-Related Quality of Life and Tamoxifen in Breast Cancer Prevention: A Report From the National Surgical Adjuvant Breast and Bowel Project P-1 Study

Richard Day, Patricia A. Ganz, Joseph P. Costantino, Walter M. Cronin, D. Lawrence Wickerham, Bernard Fisher

From the National Surgical Adjuvant Breast and Bowel Project (NSABP) Operations and Biostatistical Centers, Pittsburgh, PA, and Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA.

Address reprint requests to Richard Day, PhD, Department of Biostatistics, Graduate School of Public Health, 130 DeSoto St, University of Pittsburgh, Pittsburgh, PA 15261; email rdfac{at}vms.cis.pitt.edu

PURPOSE: This is the initial report from the health-related quality of life (HRQL) component of the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial. This report provides an overview of HRQL findings, comparing tamoxifen and placebo groups, and advice to clinicians counseling women about the use of tamoxifen in a prevention setting.

PATIENTS AND METHODS: This report covers the baseline and the first 36 months of follow-up data on 11,064 women recruited over the first 24 months of the study. Findings are presented from the Center for Epidemiological Studies–Depression Scale (CES-D), the Medical Outcomes Study 36-Item Short Form Health Status Survey (MOS SF-36) and sexual functioning scale, and a symptom checklist.

RESULTS: No differences were found between placebo and tamoxifen groups for the proportion of participants scoring above a clinically significant level on the CES-D. No differences were found between groups for the MOS SF-36 summary physical and mental scores. The mean number of symptoms reported was consistently higher in the tamoxifen group and was associated with vasomotor and gynecologic symptoms. Significant increases were found in the proportion of women on tamoxifen reporting problems of sexual functioning at a definite or serious level, although overall rates of sexual activity remained similar.

CONCLUSION: Women need to be informed of the increased frequency of vasomotor and gynecologic symptoms and problems of sexual functioning associated with tamoxifen use. Weight gain and depression, two clinical problems anecdotally associated with tamoxifen treatment, were not increased in frequency in this trial in healthy women, which is good news that also needs to be communicated.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
K. Visvanathan, R. T. Chlebowski, P. Hurley, N. F. Col, M. Ropka, D. Collyar, M. Morrow, C. Runowicz, K. I. Pritchard, K. Hagerty, et al.
American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction
J. Clin. Oncol., July 1, 2009; 27(19): 3235 - 3258.
[Abstract] [Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
M. C. Mahoney, T. Bevers, E. Linos, and W. C. Willett
Opportunities and Strategies for Breast Cancer Prevention Through Risk Reduction
CA Cancer J Clin, November 3, 2008; (2008) CA.2008.0016v1.
[Abstract] [Full Text]

Home page
 JCOHome page
E. P. Mamounas, J.-H. Jeong, D. L. Wickerham, R. E. Smith, P. A. Ganz, S. R. Land, A. Eisen, L. Fehrenbacher, W. B. Farrar, J. N. Atkins, et al.
Benefit From Exemestane As Extended Adjuvant Therapy After 5 Years of Adjuvant Tamoxifen: Intention-to-Treat Analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial
J. Clin. Oncol., April 20, 2008; 26(12): 1965 - 1971.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. W. Goodwin, S. J. Green, C. M. Moinpour, J. D. Bearden III, J. K. Giguere, C. S. Jiang, S. M. Lippman, S. Martino, and K. S. Albain
Phase III Randomized Placebo-Controlled Trial of Two Doses of Megestrol Acetate as Treatment for Menopausal Symptoms in Women With Breast Cancer: Southwest Oncology Group Study 9626
J. Clin. Oncol., April 1, 2008; 26(10): 1650 - 1656.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Trinkaus, S. Chin, W. Wolfman, C. Simmons, and M. Clemons
Should Urogenital Atrophy in Breast Cancer Survivors Be Treated with Topical Estrogens?
Oncologist, March 1, 2008; 13(3): 222 - 231.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. U. Lin and E. P. Winer
Advances in Adjuvant Endocrine Therapy for Postmenopausal Women
J. Clin. Oncol., February 10, 2008; 26(5): 798 - 805.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. L. Kahn
Moving Research From Bench to Bedside to Community: There Is Still More to Do
J. Clin. Oncol., February 1, 2008; 26(4): 523 - 526.
[Full Text] [PDF]

Home page
 JCOHome page
P. A. Ganz and C. C. Gotay
Use of Patient-Reported Outcomes in Phase III Cancer Treatment Trials: Lessons Learned and Future Directions
J. Clin. Oncol., November 10, 2007; 25(32): 5063 - 5069.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Decensi, S. Gandini, D. Serrano, M. Cazzaniga, M. Pizzamiglio, F. Maffini, G. Pelosi, C. Daldoss, U. Omodei, H. Johansson, et al.
Randomized Dose-Ranging Trial of Tamoxifen at Low Doses in Hormone Replacement Therapy Users
J. Clin. Oncol., September 20, 2007; 25(27): 4201 - 4209.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Leining, S Gelber, R Rosenberg, M Przypyszny, E. Winer, and A. Partridge
Menopausal-type symptoms in young breast cancer survivors
Ann. Onc., December 1, 2006; 17(12): 1777 - 1782.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. B. Claus, S. Petruzella, D. Carter, and S. Kasl
Quality of Life for Women Diagnosed With Breast Carcinoma in Situ
J. Clin. Oncol., October 20, 2006; 24(30): 4875 - 4881.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. Eng-Wong, J. C. Reynolds, D. Venzon, D. Liewehr, S. Gantz, D. Danforth, E. T. Liu, C. Chow, and J. Zujewski
Effect of Raloxifene on Bone Mineral Density in Premenopausal Women at Increased Risk of Breast Cancer
J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3941 - 3946.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
I. Sestak, R. Kealy, R. Edwards, J. Forbes, and J. Cuzick
Influence of Hormone Replacement Therapy on Tamoxifen-Induced Vasomotor Symptoms
J. Clin. Oncol., August 20, 2006; 24(24): 3991 - 3996.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
W. J. Gradishar and D. Cella
Selective Estrogen Receptor Modulators and Prevention of Invasive Breast Cancer
JAMA, June 21, 2006; 295(23): 2784 - 2786.
[Full Text] [PDF]

Home page
 JAMAHome page
S. R. Land, D. L. Wickerham, J. P. Costantino, M. W. Ritter, V. G. Vogel, M. Lee, E. R. Pajon, J. L. Wade III, S. Dakhil, J. B. Lockhart Jr, et al.
Patient-Reported Symptoms and Quality of Life During Treatment With Tamoxifen or Raloxifene for Breast Cancer Prevention: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial
JAMA, June 21, 2006; 295(23): 2742 - 2751.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. J. Kelloff, S. M. Lippman, A. J. Dannenberg, C. C. Sigman, H. L. Pearce, B. J. Reid, E. Szabo, V. C. Jordan, M. R. Spitz, G. B. Mills, et al.
Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer--A Plan to Move Forward
Clin. Cancer Res., June 15, 2006; 12(12): 3661 - 3697.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. A. Bardwell, L. Natarajan, J. E. Dimsdale, C. L. Rock, J. E. Mortimer, K. Hollenbach, and J. P. Pierce
Objective Cancer-Related Variables Are Not Associated With Depressive Symptoms in Women Treated for Early-Stage Breast Cancer
J. Clin. Oncol., June 1, 2006; 24(16): 2420 - 2427.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. H. Boekhout, J. H. Beijnen, and J. H.M. Schellens
Symptoms and treatment in cancer therapy-induced early menopause.
Oncologist, June 1, 2006; 11(6): 641 - 654.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. J. Whelan and K. I. Pritchard
Managing Patients on Endocrine Therapy: Focus on Quality-of-Life Issues
Clin. Cancer Res., February 1, 2006; 12(3): 1056s - 1060s.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. R. Bouknight, C. J. Bradley, and Z. Luo
Correlates of Return to Work for Breast Cancer Survivors
J. Clin. Oncol., January 20, 2006; 24(3): 345 - 353.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Guerrieri-Gonzaga, C. Robertson, B. Bonanni, D. Serrano, M. Cazzaniga, S. Mora, M. Gulisano, H. Johansson, F. Formelli, M. Intra, et al.
Preliminary Results on Safety and Activity of a Randomized, Double-Blind, 2 x 2 Trial of Low-Dose Tamoxifen and Fenretinide for Breast Cancer Prevention in Premenopausal Women
J. Clin. Oncol., January 1, 2006; 24(1): 129 - 135.
[Abstract] [Full Text] [PDF]

Home page
 J. Gen. Virol.Home page
S. M. Barratt-Boyes, A. C. Soloff, W. Gao, E. Nwanegbo, X. Liu, P. A. Rajakumar, K. N. Brown, P. D. Robbins, M. Murphey-Corb, R. D. Day, et al.
Broad cellular immunity with robust memory responses to simian immunodeficiency virus following serial vaccination with adenovirus 5- and 35-based vectors
J. Gen. Virol., January 1, 2006; 87(1): 139 - 149.
[Abstract] [Full Text] [PDF]

Home page
 Psychiatr. Serv.Home page
D. A. Monti, R. Mago, and E. J. S. Kunkel
Practical Geriatrics: Depression, Cognition, and Anxiety Among Postmenopausal Women With Breast Cancer
Psychiatr Serv, November 1, 2005; 56(11): 1353 - 1355.
[Full Text] [PDF]

Home page
 J Natl Cancer Inst MonogrHome page
L. Nekhlyudov, M. Bower, L. J. Herrinton, A. Altschuler, S. M. Greene, S. Rolnick, J. G. Elmore, E. L. Harris, A. Liu, K. M. Emmons, et al.
Women's Decision-Making Roles Regarding Contralateral Prophylactic Mastectomy
J Natl Cancer Inst Monographs, November 1, 2005; 2005(35): 55 - 60.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
V. Stearns, R. Slack, N. Greep, R. Henry-Tilman, M. Osborne, C. Bunnell, L. Ullmer, A. Gallagher, J. Cullen, E. Gehan, et al.
Paroxetine Is an Effective Treatment for Hot Flashes: Results From a Prospective Randomized Clinical Trial
J. Clin. Oncol., October 1, 2005; 23(28): 6919 - 6930.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. J. Whelan, P. E. Goss, J. N. Ingle, J. L. Pater, D. Tu, K. Pritchard, S. Liu, L. E. Shepherd, M. Palmer, N. J. Robert, et al.
Assessment of Quality of Life in MA.17: A Randomized, Placebo-Controlled Trial of Letrozole After 5 Years of Tamoxifen in Postmenopausal Women
J. Clin. Oncol., October 1, 2005; 23(28): 6931 - 6940.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. L. Stanton, P. A. Ganz, L. Kwan, B. E. Meyerowitz, J. E. Bower, J. L. Krupnick, J. H. Rowland, B. Leedham, and T. R. Belin
Outcomes From the Moving Beyond Cancer Psychoeducational, Randomized, Controlled Trial With Breast Cancer Patients
J. Clin. Oncol., September 1, 2005; 23(25): 6009 - 6018.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. E. Davidson, A. M. O'Neill, A. M. Vukov, C. K. Osborne, S. Martino, D. R. White, and M. D. Abeloff
Chemoendocrine Therapy for Premenopausal Women With Axillary Lymph Node-Positive, Steroid Hormone Receptor-Positive Breast Cancer: Results From INT 0101 (E5188)
J. Clin. Oncol., September 1, 2005; 23(25): 5973 - 5982.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. E. Avis, S. Crawford, and J. Manuel
Quality of Life Among Younger Women With Breast Cancer
J. Clin. Oncol., May 20, 2005; 23(15): 3322 - 3330.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
A. L. Stanton, C. A. Bernaards, and P. A. Ganz
The BCPT Symptom Scales: A Measure of Physical Symptoms for Women Diagnosed With or at Risk for Breast Cancer
J Natl Cancer Inst, March 16, 2005; 97(6): 448 - 456.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. H. Kroenke, W. Y. Chen, B. Rosner, and M. D. Holmes
Weight, Weight Gain, and Survival After Breast Cancer Diagnosis
J. Clin. Oncol., March 1, 2005; 23(7): 1370 - 1378.
[Abstract] [Full Text] [PDF]

Home page
 J Natl Cancer Inst MonogrHome page
J. Mandelblatt, C. Armetta, K. R. Yabroff, W. Liang, and W. Lawrence
Descriptive Review of the Literature on Breast Cancer Outcomes: 1990 Through 2000
J Natl Cancer Inst Monographs, October 1, 2004; 2004(33): 8 - 44.
[Abstract] [Full Text] [PDF]

Home page
 J Natl Cancer Inst MonogrHome page
C. C. Gotay
Assessing Cancer-Related Quality of Life Across a Spectrum of Applications
J Natl Cancer Inst Monographs, October 1, 2004; 2004(33): 126 - 133.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. K. Fink, J. Gurwitz, W. Rakowski, E. Guadagnoli, and R. A. Silliman
Patient Beliefs and Tamoxifen Discontinuance in Older Women With Estrogen Receptor--Positive Breast Cancer
J. Clin. Oncol., August 15, 2004; 22(16): 3309 - 3315.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
K. L. Taylor, R. Shelby, E. Gelmann, and C. McGuire
Quality of Life and Trial Adherence Among Participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
J Natl Cancer Inst, July 21, 2004; 96(14): 1083 - 1094.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
P. A. Ganz, L. Kwan, A. L. Stanton, J. L. Krupnick, J. H. Rowland, B. E. Meyerowitz, J. E. Bower, and T. R. Belin
Quality of Life at the End of Primary Treatment of Breast Cancer: First Results From the Moving Beyond Cancer Randomized Trial
J Natl Cancer Inst, March 3, 2004; 96(5): 376 - 387.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Cullen, M. D. Schwartz, W. F. Lawrence, J. V. Selby, and J. S. Mandelblatt
Short-Term Impact of Cancer Prevention and Screening Activities on Quality of Life
J. Clin. Oncol., March 1, 2004; 22(5): 943 - 952.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. A. Ganz, G. A. Greendale, L. Petersen, B. Kahn, and J. E. Bower
Breast Cancer in Younger Women: Reproductive and Late Health Effects of Treatment
J. Clin. Oncol., November 15, 2003; 21(22): 4184 - 4193.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
J. J. Dignam, K. Wieand, K. A. Johnson, B. Fisher, L. Xu, and E. P. Mamounas
Obesity, Tamoxifen Use, and Outcomes in Women With Estrogen Receptor-Positive Early-Stage Breast Cancer
J Natl Cancer Inst, October 1, 2003; 95(19): 1467 - 1476.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. L. Sabichi, M.-F. Demierre, E. T. Hawk, C. E. Lerman, and S. M. Lippman
Frontiers in Cancer Prevention Research
Cancer Res., September 15, 2003; 63(18): 5649 - 5655.
[Full Text] [PDF]

Home page
 JCOHome page
M. Nystedt, G. Berglund, C. Bolund, T. Fornander, and L. E. Rutqvist
Side Effects of Adjuvant Endocrine Treatment in Premenopausal Breast Cancer Patients: A Prospective Randomized Study
J. Clin. Oncol., May 1, 2003; 21(9): 1836 - 1844.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
V. G. Vogel, J. P. Costantino, D. L. Wickerham, and W. M. Cronin
National Surgical Adjuvant Breast and Bowel Project Update: Prevention Trials and Endocrine Therapy of Ductal Carcinoma in Situ
Clin. Cancer Res., January 1, 2003; 9(1): 495s - 501s.
[Abstract] [Full Text]

Home page
 JCOHome page
T. Whelan
A Trial of Two Questions
J. Clin. Oncol., October 15, 2002; 20(20): 4135 - 4138.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
S. M. Lippman and W. K. Hong
Cancer Prevention Science and Practice
Cancer Res., September 15, 2002; 62(18): 5119 - 5125.
[Full Text] [PDF]

Home page
 JCOHome page
R. T. Chlebowski, N. Col, E. P. Winer, D. E. Collyar, S. R. Cummings, V. G. Vogel III, H. J. Burstein, A. Eisen, I. Lipkus, and D. G. Pfister
American Society of Clinical Oncology Technology Assessment of Pharmacologic Interventions for Breast Cancer Risk Reduction Including Tamoxifen, Raloxifene, and Aromatase Inhibition
J. Clin. Oncol., August 1, 2002; 20(15): 3328 - 3343.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
L. S. Kinsinger, R. Harris, S. H. Woolf, H. C. Sox, and K. N. Lohr
Chemoprevention of Breast Cancer: A Summary of the Evidence for the U.S. Preventive Services Task Force
Ann Intern Med, July 2, 2002; 137(1): 59 - 69.
[Abstract] [Full Text] [PDF]

Home page
 Psychosom. Med.Home page
L. D. Cameron, H. Leventhal, R. R. Love, and L. J. Patrick-Miller
Trait Anxiety and Tamoxifen Effects on Bone Mineral Density and Sex Hormone- Binding Globulin
Psychosom Med, July 1, 2002; 64(4): 612 - 620.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. N. Levine and P. A. Ganz
Beyond the Development of Quality-of-Life Instruments: Where Do We Go From Here?
J. Clin. Oncol., May 1, 2002; 20(9): 2215 - 2216.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
T. Ernst, L. Chang, D. Cooray, C. Salvador, J. Jovicich, I. Walot, K. Boone, and R. Chlebowski
The Effects of Tamoxifen and Estrogen on Brain Metabolism in Elderly Women
J Natl Cancer Inst, April 17, 2002; 94(8): 592 - 597.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
V. G. Vogel
Prevention in the Balance
Oncologist, April 1, 2002; 7(2): 103 - 105.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
P. A. Ganz, K. A. Desmond, B. Leedham, J. H. Rowland, B. E. Meyerowitz, and T. R. Belin
Quality of Life in Long-Term, Disease-Free Survivors of Breast Cancer: a Follow-up Study
J Natl Cancer Inst, January 2, 2002; 94(1): 39 - 49.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
V. C. Jordan and M. Morrow
Chemoprevention of Breast Cancer: A Model for Change
J. Clin. Oncol., January 1, 2002; 20(1): 1 - 3.
[Full Text] [PDF]

Home page
 J Natl Cancer Inst MonogrHome page
P. A. Ganz
Impact of Tamoxifen Adjuvant Therapy on Symptoms, Functioning, and Quality of Life
J Natl Cancer Inst Monographs, December 1, 2001; 2001(30): 130 - 134.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
R. Day, P. A. Ganz, and J. P. Costantino
Tamoxifen and Depression: More Evidence From the National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention (P-1) Randomized Study
J Natl Cancer Inst, November 7, 2001; 93(21): 1615 - 1623.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Klein, M. J.B . Taphoorn, J. J. Heimans, H. M. van der Ploeg, W. P. Vandertop, E. F. Smit, S. Leenstra, C. A.F. Tulleken, W. Boogerd, J. S.A. Belderbos, et al.
Neurobehavioral Status and Health-Related Quality of Life in Newly Diagnosed High-Grade Glioma Patients
J. Clin. Oncol., October 15, 2001; 19(20): 4037 - 4047.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
V. C. Jordan, S. Gapstur, and M. Morrow
Selective Estrogen Receptor Modulation and Reduction in Risk of Breast Cancer, Osteoporosis, and Coronary Heart Disease
J Natl Cancer Inst, October 3, 2001; 93(19): 1449 - 1457.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
C. L. Shapiro and A. Recht
Side Effects of Adjuvant Treatment of Breast Cancer
N. Engl. J. Med., June 28, 2001; 344(26): 1997 - 2008.
[Full Text] [PDF]

Home page
 JCOHome page
L. Fallowfield, A. Fleissig, R. Edwards, A. West, T. J. Powles, A. Howell, and J. Cuzick
Tamoxifen for the Prevention of Breast Cancer: Psychosocial Impact on Women Participating in Two Randomized Controlled Trials
J. Clin. Oncol., April 1, 2001; 19(7): 1885 - 1892.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
H. J. Burstein and E. P. Winer
Primary Care for Survivors of Breast Cancer
N. Engl. J. Med., October 12, 2000; 343(15): 1086 - 1094.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
C. C. Gotay, C. M. Moinpour, S. Moody-Thomas, E. R. Gritz, K. S. Albain, E. DeAntoni, L. Hansen, and P. A. Ganz
Behavioral Science Research in the Cooperative Group Setting: the Southwest Oncology Group Experience
J Natl Cancer Inst, September 6, 2000; 92(17): 1381 - 1387.
[Full Text] [PDF]

Home page
 NEJMHome page
R. T. Chlebowski
Reducing the Risk of Breast Cancer
N. Engl. J. Med., July 20, 2000; 343(3): 191 - 198.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
P. A. Ganz, G. A. Greendale, L. Petersen, L. Zibecchi, B. Kahn, and T. R. Belin
Managing Menopausal Symptoms in Breast Cancer Survivors: Results of a Randomized Controlled Trial
J Natl Cancer Inst, July 5, 2000; 92(13): 1054 - 1064.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. M. Moinpour, L. C. Lovato, I. M. Thompson Jr, J. E. Ware Jr, P. A. Ganz, D. L. Patrick, S. A. Shumaker, G. W. Donaldson, A. Ryan, and C. A. Coltman Jr
Profile of Men Randomized to the Prostate Cancer Prevention Trial: Baseline Health-Related Quality of Life, Urinary and Sexual Functioning, and Health Behaviors
J. Clin. Oncol., May 9, 2000; 18(9): 1942 - 1953.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
S. M. Lippman and P. H. Brown
Tamoxifen Prevention of Breast Cancer: an Instance of the Fingerpost
J Natl Cancer Inst, November 3, 1999; 91(21): 1809 - 1819.
[Full Text] [PDF]

Home page
 JCOHome page
J. J. Beitler, J. E. Mortimer, and D. Knapp
Tamoxifen and Sexuality: Let's Listen to the Data Speak
J. Clin. Oncol., November 1, 1999; 17(11): 3689 - 3690.
[Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 1999 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online